15 million persons in the US will be living with mild cognitive impairment due to Alzheimer disease (AD) or clinical AD by 2060, a recent study predicts. Furthermore, since large numbers of persons are living with preclinical AD, these results underscore the need for secondary preventions for persons with existing AD brain pathology who are likely to develop clinical disease during their lifetimes, as well as primary preventions for persons without preclinical disease. Researchers used a multistate model incorporating biomarkers for preclinical AD with US population projections. They found:
- Approximately 6.08 million Americans had either clinical AD or mild cognitive impairment due to AD in 2017 and that will grow to 15 million by 2060.
- In 2017, 46.7 million Americans had preclinical AD (amyloidosis, neurodegeneration, or both), although many may not progress to clinical disease during their lifetimes.
- Primary and secondary preventions have differential impact on future disease burden.
Brookmeyer R, Abdalla N, Kawas CH, Corrada MM. Forecasting the prevalence of preclinical and clinical Alzheimer's disease in the United States. [Published online ahead of print December 6, 2017]. Alzheimers Dement. doi:10.1016/j.jalz.2017.10.009.
Must Reads in Alzheimer's & Cognition
No Association Between Self-Reported TBI and AD, Alzheimers Dement; ePub 2019 Mar 6; Sugarman, et al
Ethnoracial Differences Found in Alzheimer Disease, Alzheimers Dement; ePub 2019 Feb 18; Santosa, et al
Genetic Basis of Motoric Cognitive Risk Syndrome, Neurology; ePub 2019 Feb 8; Sathyan, et al
Facial Expression Recognition Preservation Examined, Neurology; ePub 2019 Feb 8; Pressman, et al